Truveta Research study : At 52 weeks, weight loss was 18.2% for Mounjaro (tirzepatide ADM) compared to 10.6% for Ozempic (semaglutide ADM) for patients without type 2 diabetes (T2D) The lower percentages in the Truveta Research study likely reflect a shorter timeframe (52 weeks instead of 72) and the use of ADM versions, which can have lower doses
Brighter skin tone : Copper peptides help fade post-inflammatory hyperpigmentation, leading to a more radiant and even complexion
Folic Acid and Vitamin B12 supplement for the treatment of macrocytic anaemia in horses and dogs
First-time prescribing rates (first-time GLP-1 RA prescriptions per total prescriptions) increased 12.02% in March 2025 compared to December 2024
Conversations That Move the Field Forward Join leading endocrinologists, researchers, and healthcare decision-makers for real talk on the latest in GLP-1 research
Regular consultations with your healthcare provider are crucial during this phase to monitor your blood sugar management, assess weight management progress, and adjust your treatment plan as necessary for optimal outcomes
